Last reviewed · How we verify
Ablysinol — Competitive Intelligence Brief
marketed
ethanol
GABA A receptor alpha-4/beta-2/delta
Metabolic
Small molecule
Live · refreshed every 30 min
Target snapshot
Ablysinol (Ethanol) — Qol Medcl.
Comparator set (2 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Ablysinol TARGET | Ethanol | Qol Medcl | marketed | ethanol | GABA A receptor alpha-4/beta-2/delta | 1946-01-01 |
| Ethamolin | ETHANOLAMINE OLEATE | Qol Medcl | marketed | ethanolamine oleate | 1988-01-01 | |
| Phenoxethol | phenoxyethanol | marketed | phenoxyethanol |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (ethanol class)
- Qol Medcl · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Ablysinol CI watch — RSS
- Ablysinol CI watch — Atom
- Ablysinol CI watch — JSON
- Ablysinol alone — RSS
- Whole ethanol class — RSS
Cite this brief
Drug Landscape (2026). Ablysinol — Competitive Intelligence Brief. https://druglandscape.com/ci/ethanol. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab